

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



EuroEyes International Eye Clinic Limited
德視佳國際眼科有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1846)

**VOLUNTARY ANNOUNCEMENT –
INTENTION TO CONDUCT ON-MARKET SHARE REPURCHASE**

The board (the “**Board**”) of directors (the “**Directors**” and each a “**Director**”) of EuroEyes International Eye Clinic Limited (the “**Company**”) wishes to announce its intention to exercise the powers of the Company under the general mandate (the “**Repurchase Mandate**”) granted to the Directors pursuant to the resolutions of the shareholders of the Company (the “**Shareholders**”) passed at the annual general meeting held on 31 May 2023, to repurchase shares of the Company (the “**Shares**”) not exceeding 10% of the total number of Shares in issue as at 31 May 2023 (i.e., 33,324,000 Shares).

The Repurchase Mandate will continue in force until (i) the conclusion of the next annual general meeting of the Company; (ii) the expiry of the period within which the next annual general meeting of the Company is required by any applicable laws or the articles of association of the Company to be held; or (iii) the passing of an ordinary resolution by the Shareholders in general meeting revoking or varying the authority given to the Directors by the ordinary resolution approving the Repurchase Mandate, whichever is the earliest.

On 26 April 2024, the Board formally resolved to utilize the Repurchase Mandate and, subject to market conditions, the Company may repurchase the Shares in open market from time to time up to a maximum of 3% of the total number of issued Shares as at the date of this announcement (i.e., not exceeding 9,997,200 Shares on the basis of 333,240,000 Shares in issue as at 31 May 2023) (the “**Proposed Repurchase**”). The Proposed Repurchase will be funded by internal financial resources of the Company.

The Company will conduct the Proposed Repurchase in compliance with the second amended and restated memorandum and articles of association of the Company, the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”), the Codes on Takeovers and Mergers and Share Buy-backs (the “**Takeovers Code**”), the Companies Act of the Cayman Islands and all applicable laws and regulations to which the Company is subject to.

The Board considers that the Proposed Repurchase is in the best interest of the Company and the Shareholders as a whole. The Proposed Repurchase reflects the Company’s recognition of its own value and its confidence in the long-term prospects of the industry. The Board believes that the current financial resources of the Company would enable it to implement the Proposed Repurchase while maintaining a solid financial position.

As at the date of this announcement, the Board has no intention to repurchase Shares to an extent that will trigger the obligations under the Takeovers Code to make a mandatory offer. The Board will ensure that the Company continues to satisfy the minimum public float requirement under the Listing Rules before and after the Proposed Repurchase. There have been no material changes to the particulars contained in the Explanatory Statement as set out in the circular of the Company dated 28 April 2023.

As at the date of this announcement, the Company has not repurchased any Shares. Shareholders and potential investors of the Company should note that any repurchase of Shares may be done subject to the market conditions and at the Board's absolute discretion. There is no assurance of the timing, quantity or price of any repurchase of Shares. Shareholders and potential investors of the Company should therefore exercise caution when dealing in the Shares.

By Order of the Board
EuroEyes International Eye Clinic Limited
Dr. Jørn Slot Jørgensen
Chairman and Executive Director

Hong Kong, 26 April 2024

As at the date of this announcement, the Board comprises Dr. Jørn Slot Jørgensen, Dr. Markus Braun, Mr. Jannik Jonas Slot Jørgensen and Professor Dan Zoltan Reinstein as executive Directors; Mr. Marcus Huascar Bracklo as non-executive Director; and Mr. Hans Helmuth Hennig, Ms. Katherine Rong Xin and Mr. Philip Duncan Wright as independent non-executive Directors.